These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 20824401)

  • 1. A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma.
    Takamatsu Y; Sunami K; Hata H; Nagafuji K; Choi I; Higuchi M; Uozumi K; Masaki Y; Tamura K;
    Int J Hematol; 2010 Oct; 92(3):503-9. PubMed ID: 20824401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
    Harrison SJ; Quach H; Link E; Seymour JF; Ritchie DS; Ruell S; Dean J; Januszewicz H; Johnstone R; Neeson P; Dickinson M; Nichols J; Prince HM
    Blood; 2011 Dec; 118(24):6274-83. PubMed ID: 21911830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.
    Mangiacavalli S; Pochintesta L; Pascutto C; Cocito F; Pompa A; Cazzola M; Corso A
    Am J Hematol; 2013 Feb; 88(2):102-6. PubMed ID: 23224960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed or refractory multiple myeloma: a multicenter phase 2 study.
    Takamatsu Y; Sunami K; Muta T; Morimoto H; Miyamoto T; Higuchi M; Uozumi K; Hata H; Tamura K;
    Int J Hematol; 2013 Aug; 98(2):179-85. PubMed ID: 23832805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.
    Romano A; Chiarenza A; Conticello C; Cavalli M; Vetro C; Di Raimondo C; Cunsolo R; Palumbo GA; Di Raimondo F
    Eur J Haematol; 2014 Sep; 93(3):207-13. PubMed ID: 24673398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
    Waterman GN; Yellin O; Swift RA; Mapes R; Eades B; Ackerman E; Berenson JR
    Ann Hematol; 2011 Feb; 90(2):193-200. PubMed ID: 20809423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
    Richardson PG; Weller E; Jagannath S; Avigan DE; Alsina M; Schlossman RL; Mazumder A; Munshi NC; Ghobrial IM; Doss D; Warren DL; Lunde LE; McKenney M; Delaney C; Mitsiades CS; Hideshima T; Dalton W; Knight R; Esseltine DL; Anderson KC
    J Clin Oncol; 2009 Dec; 27(34):5713-9. PubMed ID: 19786667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma.
    Lee KW; Yun T; Song EK; Na II; Shin H; Bang SM; Lee JH; Lee ST; Kim JH; Yoon SS; Lee JS; Park S; Kim BK; Kim NK
    J Korean Med Sci; 2005 Aug; 20(4):598-62. PubMed ID: 16100450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib and dexamethasone for Japanese patients with relapsed and refractory multiple myeloma: a single center experience.
    Igarashi N; Chou T; Hirose T; Imai Y; Ishiguro T
    Int J Hematol; 2010 Oct; 92(3):518-23. PubMed ID: 20886379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy comparison between standard and reduced doses of bortezomib combined with adriamycin and dexamethasone in the treatment of patients with multiple myeloma].
    Gu HT; Shu MM; Gao GX; Dong BX; Liang R; Yang L; Bai QX; Zhang T; Zhang YQ; Chen XQ
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):622-5. PubMed ID: 23906459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma.
    Kusumoto S; Sunami K; Inagaki M; Iida S
    Int J Hematol; 2015 Jun; 101(6):578-84. PubMed ID: 25749662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [PAD regimen for relapsed or refractory patients with multiple myeloma].
    Zhang YQ; Liang R; Bai QX; Zhang T; Yang L; Wang YW; Wang WQ; Gu HT; Shu MM; Zhu HF; Bai YN; Chen XQ
    Zhonghua Xue Ye Xue Za Zhi; 2009 Apr; 30(4):260-3. PubMed ID: 19731828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.
    Lee SS; Suh C; Kim BS; Chung J; Joo YD; Ryoo HM; Do YR; Jin JY; Kang HJ; Lee GW; Lee MH; Shim H; Kim K; Yoon SS; Bang SM; Kim HY; Lee JJ; Park J; Lee DS; Lee JH;
    Ann Hematol; 2010 Sep; 89(9):905-12. PubMed ID: 20349060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
    Popat R; Oakervee H; Williams C; Cook M; Craddock C; Basu S; Singer C; Harding S; Foot N; Hallam S; Odeh L; Joel S; Cavenagh J
    Br J Haematol; 2009 Mar; 144(6):887-94. PubMed ID: 19183191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
    Offidani M; Corvatta L; Polloni C; Gentili S; Mele A; Rizzi R; Catarini M; Caraffa P; Samori A; Blasi N; Ferranti M; Malerba L; Brunori M; Leoni P
    Ann Hematol; 2011 Dec; 90(12):1449-56. PubMed ID: 21437586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
    Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; San-Miguel JF; Bladé J; Boccadoro M; Cavenagh J; Dalton WS; Boral AL; Esseltine DL; Porter JB; Schenkein D; Anderson KC;
    N Engl J Med; 2005 Jun; 352(24):2487-98. PubMed ID: 15958804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma.
    Ning YM; He K; Dagher R; Sridhara R; Farrell AT; Justice R; Pazdur R
    Oncology (Williston Park); 2007 Nov; 21(12):1503-8; discussion 1511, 1513, 1516 passim. PubMed ID: 18077994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
    Yuan ZG; Jin J; Huang XJ; Li Y; Chen WM; Liu ZG; Chen XQ; Shen ZX; Hou J
    Chin Med J (Engl); 2011 Oct; 124(19):2969-74. PubMed ID: 22040537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.
    Ludwig H; Kasparu H; Leitgeb C; Rauch E; Linkesch W; Zojer N; Greil R; Seebacher A; Pour L; Weißmann A; Adam Z
    Blood; 2014 Feb; 123(7):985-91. PubMed ID: 24227817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of relapsed and refractory myeloma.
    Kaufman J; Gleason C; Lonial S
    Curr Hematol Malig Rep; 2009 Apr; 4(2):99-107. PubMed ID: 20425421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.